Contemporary Molecular Classification of Urinary Bladder Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Bladder cancer displays significant clinical outcome heterogeneity, suggesting underlying biological differences.
• Transcriptional profiling has identified distinct molecular subtypes: basal and luminal.

Purpose of the Study:

• To review the historical research and recent advancements in molecular classification of bladder cancer.
• To emphasize the clinical implications of bladder cancer subtypes regarding prognosis and targeted therapy response.

Main Methods:

• Review of existing literature on bladder cancer molecular subtypes.
• Analysis of transcriptional profiling data.
• Correlation of molecular subtypes with clinical outcomes and treatment responses.

Main Results:

• Luminal bladder tumors are characterized by urothelial differentiation markers and respond better to FGFR3-targeted therapies.
• Basal bladder tumors express basal cell markers, show potential squamous differentiation, and have a worse prognosis but better response to immune checkpoint inhibitors.
• Squamous differentiation in bladder tumors predicts response to epidermal growth factor receptor inhibitors.

Conclusions:

• Bladder cancer molecular subtypes (basal, luminal, squamous) are associated with differential prognoses and responses to specific therapies.
• Molecular subtyping holds promise for guiding personalized treatment strategies in bladder cancer management.
• Further prospective studies are needed to integrate molecular subtyping into routine clinical practice for bladder cancer.